Cost-effectiveness of golimumab (Simponi®) in the treatment of moderate to severe rheumatoid arthritis.
|20/11/2009||11/05/2010||Reimbursement recommended following price review, June 2010.|
The review group did not consider golimumab cost-effective at the submitted price in May 2010.
Following a price reduction the review group now consider golimumab to be cost-effective. June 2010.